US and EU reviewing risks of Abbott's sibutramine
This article was originally published in Scrip
Executive Summary
Both the US FDA and the EU's CHMP are reviewing "preliminary data" suggesting that patients taking Abbott Laboratories' diet drug Meridia (sibutramine monohydrate) have a higher risk of cardiovascular problems than patients taking placebo.